Evaluating Treatment Response of Chronic Myeloid Leukemia: Emerging Science and Technology

Author(s): Antonia Cagnetta, Anna Garuti, Carlo Marani, Michele Cea, Maurizio Miglino, Ilaria Rocco, Claudia Palermo, Giuseppina Fugazza, Gabriella Cirmena, Nicoletta Colombo, Raffaella Grasso, Alessio Nencioni, Marco Gobbi, Franco Patrone.

Journal Name: Current Cancer Drug Targets

Volume 13 , Issue 7 , 2013

Become EABM
Become Reviewer


Chronic myeloid leukemia (CML) is a hematological disease accounting for about 15-20% of all adult leukemias. The clinical and biologic advances achieved in such a malignancy, represent one of the best successes obtained by translational medicine. Indeed, identification of the fusion oncogene BCR-ABL has allowed using of small molecule inhibitors of its tyrosine kinase activity which, in turn, have literally revolutionized the treatment of CML. Importantly the successfully clinical management was also realized on appropriate diagnosis, disease monitoring as well as early identification of such mutations causing drug resistance. Notably the recent availability of refined laboratory equipments represented by the Next Generation Sequencing (NGS) and genomic analyses has further contributed to gain ground towards the cure of this tumor. These issues are discussed here together with an overview on how patients treated with tyrosine kinase inhibitors should be monitored.

Keywords: chronic myelogenous leukemia, cytogenetic analysis, molecular monitoring, minimal residual disease, mutational analysis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [779 - 790]
Pages: 12
DOI: 10.2174/15680096113139990084
Price: $58

Article Metrics

PDF: 19